Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers—Early Experiences from Romania and Literature Review

Prognosis in recurrent/metastatic head and neck squamous-cell carcinoma (HNSCC) refractory to platinum-based chemotherapy is poor, making therapy optimization a priority. Anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody Nivolumab was approved in such cases. We present the early e...

Descripción completa

Detalles Bibliográficos
Autores principales: Mireștean, Camil Ciprian, Stan, Mihai Cosmin, Schenker, Michael, Volovăț, Constantin, Volovăț, Simona Ruxandra, Iancu, Dragoș Teodor Petru, Iancu, Roxana Irina, Bădulescu, Florinel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452972/
https://www.ncbi.nlm.nih.gov/pubmed/37627878
http://dx.doi.org/10.3390/diagnostics13162620

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452972/
https://www.ncbi.nlm.nih.gov/pubmed/37627878
http://dx.doi.org/10.3390/diagnostics13162620

Ejemplares similares